Monopar Therapeutics Inc.
MNPR
$113.04
$2.632.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.33M | 6.96M | 6.80M | 5.74M | 4.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.12M | 18.71M | 16.70M | 21.62M | 19.11M |
| Operating Income | -22.12M | -18.71M | -16.70M | -21.62M | -19.11M |
| Income Before Tax | -17.84M | -14.99M | -13.72M | -19.44M | -17.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.84 | -14.99 | -13.72 | -19.44 | -17.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.84M | -14.99M | -13.72M | -19.44M | -17.31M |
| EBIT | -22.12M | -18.71M | -16.70M | -21.62M | -19.11M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.17 | -1.90 | -1.82 | -3.44 | -3.33 |
| Normalized Basic EPS | -1.36 | -1.19 | -1.14 | -2.15 | -2.08 |
| EPS Diluted | -2.17 | -1.90 | -1.82 | -3.44 | -3.33 |
| Normalized Diluted EPS | -1.36 | -1.19 | -1.14 | -2.15 | -2.08 |
| Average Basic Shares Outstanding | 32.74M | 31.19M | 29.64M | 26.01M | 22.41M |
| Average Diluted Shares Outstanding | 32.74M | 31.19M | 29.64M | 26.01M | 22.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |